ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Selective Membrane Protein Enrichment Enables Defined Biomimetic Nanoparticles for Endothelial Targeting.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanomedicine and the tumor immune microenvironment in cancer immunotherapy: a bibliometric and knowledge-mapping analysis.Frontiers in oncology · 2026Pooled it
- Rewriting the mRNA Delivery Map: Albumin Hitchhiking Lipid Nanoparticles for Safer and Smarter Nanomedicine.ACS materials Au · 2026Review
- Biomimetic ZIF-8 Nanoplatform for Enhanced Therapeutic Efficacy of Combined Phototherapy and Chemotherapy Against Hepatocellular Carcinoma.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nanoparticles offer a promising strategy for targeted drug delivery while reducing off-target toxicity. Biomimetic nanoparticles, which integrate native cell components, enhance biological compatibility but often suffer from poorly defined protein compositions that hinder reproducibility and clinical translation. Here, we present a next-generation biomimetic approach to engineer Particular Nanoparticles (PNPs)- formulation enriched with specific, functionally relevant membrane proteins for precise control and tunability. We incorporated leukocyte adhesion proteins (including CD18, CD11a, and CD11b) into the nanoparticle membrane to enhance targeting of inflamed sites. Using a 2D microfluidic model that mimics human blood vessels, adhesion-enriched PNPs demonstrated significantly improved endothelial interactions and greater accumulation under flow at inflamed endothelium compared to conventional Leukosomes. This protein-defined biomimetic nanoparticle platform offers enhanced targeting efficiency, improved reproducibility, and translational potential for inflammation-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.